TO THE EDITOR
The BCL10 gene, originally identified through its recurrent involvement in t(1;14)(p22;q32) of the mucosa-associated lymphoid tissue (MALT) lymphoma, encodes a cytosolic protein composed of 233 amino-acid residues with proapoptotic and proinflammatory activities, whereas mutated BCL10, causing Cterminal truncation, can operate as an oncogene.
1 BCL10 is widely expressed in normal lymphoid tissues, with the expression level depending on the developmental stage of lymphocytes. 2 Many B-cell lymphomas, including MALT lymphoma, also express BCL10. 2 In contrast to the normal B cells that express BCL10 in the cytoplasm, MALT lymphoma cells with t(1;14)(p22;q32) or t(11;18)(q21;q21) translocation express the protein predominantly in the nucleus. [2] [3] [4] Recently, we reported that BCL10 is expressed in the cytoplasm of normal NK cells, and demonstrated its aberrant nuclear localization in the tumor cells of nasal NK/T-cell lymphomas (NL). 5 Many NL tumors have the same nuclear staining of BCL10 as the MALT lymphomas, but the chromosomal translocations t(1;14)(p22;q32) or t(11;18)(q21;q21) that are the hallmark of MALT lymphoma [2] [3] [4] are not present in NL, 6 implicating an alternative mechanism leading to aberrant BCL10 nuclear localization during tumorigenesis of NL. 5 In this study, we examined BCL10 gene mutations in normal NK cells and NL, and investigated whether these mutations were associated with the aberrant BCL10 localization in the nucleus in NL.
þ normal NK cells were isolated from the peripheral blood mononuclear cells (PBMC) of two healthy volunteers by cell sorting using an EPICS ALTRA cell sorter (Beckman Coulter, Miami, FL, USA). Frozen tumor blocks of 18 NL cases and 13 paraffin blocks of these cases were retrieved from the Department of Pathology, Queen Mary Hospital, the University of Hong Kong, Hong Kong. Lymphomas were diagnosed according to the World Health Organization (WHO) classification of lymphoid malignancies, as reported previously. 5 Semiquantitative RT-PCR covering the entire coding sequence of the BCL10 gene was performed using the RNA from the NK cells and NL tumor specimens with forward primer 5 0 -GGACCCGGAAGAAGCGCCATCTCC-3 0 and reverse primer 5 0 -CATTAAAAATTAAAAGGCAATAAAGTG-3 0 , corresponding to the BCL10 mRNA sequence nucleotides 657-1419 (GenBank accession no. AJ006288). A second pair of primers 5 0 -ACCAGGGCTGCTTTTAACTCT-3 0 and 5 0 -GGGTCTCTCTCTT CCTCTTGTG-3 0 were included in the reaction to amplify a 1005 bp cDNA fragment of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the internal control. RNA from 10 reactive tonsils served as positive control, whereas distilled water served as negative control. The purified PCR products were directly sequenced from both directions.
BCL10 mRNA expression was detected by RT-PCR in normal NK cells (Figure 1a ) and 16 of 18 (89%) NL cases ( Figure 1c) . No mutations were detected in the BCL10 cDNA sequences from the NK cells. However, among the 16 NL informative cases in which the full-length coding sequence could be amplified, a total of eight extra electrophoretic bands of PCR products ranging from 150 to 700 bp were observed in six cases, raising the possibility that partial sequence deletion within the BCL10 gene or altered pre-mRNA splicing might have occurred in these NL cases. As a control, RT-PCR of the RNA from 10 reactive tonsils was used, following the same protocol, which showed only wild-type PCR products ( Figure 1b) . The BCL10 cDNA sequences from the reactive tonsils were also analyzed and no mutations were detected.
DNA sequencing from the aberrant PCR products identified four types of variants, three deletion variants in two cases ( Figure 2a ) and one pattern of splicing transcripts missing the first 33 bp in the coding exon 3 sequence in five cases ( Figure 2c ). Sequencing of the normal-sized RT-PCR products showed only three known single-nucleotide polymorphisms at nucleotides 13, 24 and 638. 7 To confirm the finding of 224 bp deletion in the cDNA sequences from case 7, the DNA from the same case was examined by PCR with primers 5 0 -TGAAAAACTGAGGGCATC-CA-3 0 and 5 0 -CATTAAAAATTAAAAGGCAATAAAGTG-3 0 (nucleotides 14177-14474 GenBank accession no. AF097732). Deletion D224 was detectable in the genomic DNA sample verifying the sequencing data derived from the mRNA (Figure 2b) .
Among the five cases that had 33 bp splicing variants, NL case number 14 had a relatively strong 33 bp splice variant but only a very faint wild-type BCL10 mRNA, in contrast to the other four tumors (Figure 1c ). To determine whether 33 bp splicing is caused by mutation, the genomic DNA sequence spanning the intron 2 and coding exon 3 boundary from the related tumors was amplified by PCR with primers 5 0 -TTAACAAGTCACAA GATGGACAGTG-3 0 and 5
0 -CTAGAACAGGCAAATTCAGA GAAG-3 0 (nucleotides 14015-14277, GenBank accession no. AF097732). PCR products were directly sequenced from both directions after purification, and they were confirmed by cloning into the pGEM-T Easy vector (Promega, Madison, WI, USA), followed by sequencing of the recombinants. Analysis of the boundary sequence between intron 2 and coding exon 3 in the chromosomal DNA from NL case number 14 showed a transversional mutation from invariable T to G at the fifth nucleotide before the acceptor/splicing site of intron 2 ( Figure 2c) . No mutation was detected in the intron/exon boundary DNA sequence in the other four cases that also had 33 bp variant of pre-mRNA splicing.
We have recently reported aberrant nuclear staining of BCL10 in NL cells, and identified its close correlation with NF-kB activation in the tumor cells. 5 To determine whether BCL10 genomic mutations as summarized in the schematic diagram ( Figure 3) were associated with its aberrant nuclear localization in NL, immunostaining was performed on 13 tumor samples with paraffin blocks in this series using the monoclonal antibody clone 151. 2 Paraffin sections of lymphoid tissues such as tonsil were used as positive controls, and the negative reagent control omitting the primary antibody was included in the experiment. All the samples showed the immunoreactivity of BCL10. In addition to the cytoplasmic expression, 10 of 13 (77%) cases, including all of the cases that had BCL10 gene mutations (cases 7, 11 and 14), showed nuclear staining in a variable percentage of tumor cells (Figure 4 ). Cytospin preparations of normal NK cells and paraffin sections of reactive tonsils were also stained as controls, and only cytoplasmic staining of BCL10 was observed.
A total of four BCL10 gene mutations were detected among three NL cases. Three deletions in cases 7 and 11 caused loss of the coding sequences of the important domains of BCL10. Deletion of 224 bp in case 7 resulted in a frame-shift mutation from codon 153 onwards so that the intact N-terminal CARD motif was retained, but the distal portion of the C-terminal (c) Sequencing analysis showed that the first 33 bp mRNA sequence within the coding exon 3 was skipped by RNA splicing in case 14. Direct sequencing from both directions of the genomic DNA from the case 14 revealed a T to G transversional mutation at the fifth nucleotide before the acceptor/splicing site of intron 2 (indicated by the asterisk), and the mutation was confirmed by cloning into the pGEM-T Easy vector followed by sequencing of the recombinants. serine-/threonine-rich sequence was lost. This deletion caused the C-terminal truncation that has been shown to induce NF-kB activation and to promote the cellular transformation in vitro.
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None of the other two deletions are likely to have the same effect, as deletion of 498 bp in case 7 abrogated all the major domains of the BCL10 protein and deletion of 608 bp in case 11 removed the initiation codon from the sequence.
A point mutation was detected within the intron 2/coding exon 3 boundary of the BCL10 gene in the DNA from the one case (case 14) that had a relatively strong 33 bp splice variant but only a very faint wild-type BCL10 mRNA. Such a point mutation at the splicing site might allow a cryptic splicing site to operate and generate the BCL10 splice variant by skipping a 33 bp sequence. However, no such mutation was detected in the intron/exon boundary DNA sequence in the other four cases that had the same variant of 33 bp pre-mRNA splicing, indicating that splicing is not controlled by mutation in these cases. In this study, the splice variant was not found in the tonsillar RNA that served as the normal control. The appearance of this splice variant in the tumors but not in the reactive tonsils initially suggested its tumorigenetic role, as proposed in the early publications. 1 However, it has also been reported that this splice variant is present in bone marrow specimens from normal individuals, 8 so it seems likely that the splice variant might be a response to an altered cellular state in the tumor. In case 14, the variant-promoting mutation could be a tumorigenic event.
Overall, BCL10 deletions and mutations were detected only in a small proportion of NL cases. Of these abnormal sequences, there is only one deletion variant that is predicted to cause the BCL10 C-terminal truncation associated with NF-kB activation and loss of apoptosis signaling. Since BCL10 nuclear staining was detected much more frequently than gene mutation and was not associated with a specific type of mutation, BCL10 nuclear localization could not be related to the occurrence of BCL10 mutations in NL. Neither t(1;14)(p22;q32) nor t(11;18)(q21;q21) translocations, which are associated with BCL10 nuclear staining in MALT lymphomas, are present in NL. All these data indicate a novel, as yet undiscovered, mechanism leading to aberrant BCL10 nuclear localization during the tumorigenesis of NL.
Figure 4
BCL10 protein expression in NL. The NL tumor cells from case 11 showed moderate cytoplasmic BCL10 staining and strong BCL10 nuclear staining. Immunoperoxidase staining, original magnification, Â 400.
